Covaxin, Japan also recognizes Pfizer's Comirnaty, AstraZeneca's Vaxzevria, Moderna's Spikevax, Janssen's JCOVDEN, and Novavax's Nuvaxovid.
Last month, the Hyderabad-based company announced that the administration of the third dose of its Covid-19 vaccine Covaxin (BBV152) after six months of two-dose vaccination dramatically increased neutralizing antibody responses, and showed increased memory B cell response in subjects in controlled clinical trials.
The company said the findings are based on a comprehensive study that has demonstrated multiple benefits of Covaxin. According to Bharat Biotech, the vaccine provides benefits like long-term immune response, cell-mediated immunity, the safety of booster dose, and immunogenicity against spike protein.
Bharat Biotech said immune responses declined at six months but increased by 40-fold in subjects who received a booster dose.